Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HIMS

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks

Food and Drug Administration Commissioner Martin Makary stated on Friday that Hims Hers Health Inc. (NYSE:HIMS) broke federal law with its Super Bowl commercial promoting weight-loss drugs.

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims Hers Health Inc. (NYSE:HIMS) launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire

Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire

Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc (NYSE:RKT), Oscar Health Inc (NYSE:OSCR), and Hims Hers Health Inc (NYSE:HIMS) are sitting at the top of the market's short-interest leaderboard, each with more than a quarter of their float sold short.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

What's Going On With Hims & Hers Shares Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy.

Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

inkl

Read news from The Economist, FT, and more,
with one subscription

CoreWeave, Applied Materials And Hims & Hers Are Among Top 10 Large Cap Losers Last Week (August 11-August 15): Are The Others In Your Portfolio?

CoreWeave, Applied Materials And Hims & Hers Are Among Top 10 Large Cap Losers Last Week (August 11-August 15): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

5 Ways ‘Hims’ Searches Are Shaping Men’s Health Conversations

5 Ways ‘Hims’ Searches Are Shaping Men’s Health Conversations

In recent years, men’s health has shifted from being a quiet, private matter to an open conversation fueled by technology and data. One of the biggest players in that transformation is Hims, the telehealth platform known for discreetly delivering prescription and wellness products straight to consumers. Search data from Hims…

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims & Hers Stock Slips As FTC Probe Into Subscription Practices Resurfaces

Hims Hers Health Inc. (NYSE:HIMS) stock is trading lower following a media report revealing that the Federal Trade Commission (FTC) has been investigating the company’s business practices for over a year.

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three…

MarketBeat Week in Review – 08/04 - 08/08

Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales

Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy

Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy

Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.

Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say

Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say

Shares of Hims Hers Health Inc (NYSE:HIMS) are under pressure Tuesday, after the company reported downbeat second-quarter revenues.

Get all your
news in one place.

100's of premium titles.
One news app.

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Hims & Hers Health Stock Tumbles On Q2 Earnings As Revenue Comes Up Short, Company Sees 'Exciting Period Of Growth' Ahead

Hims Hers Health Inc (NYSE:HIMS) reported second-quarter earnings after the market close on Monday. Here’s a rundown of the report.

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Get all your
news in one place.

100's of premium titles.
One news app.

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Hims & Hers Stock Could Rocket To Meme Stock Fame — If Short Sellers Feel The Squeeze

Hims Hers Health, Inc. (NYSE:HIMS) has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally.

What's Going On With Hims & Hers Stock Wednesday?

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

The Independent UK

‘Drunk’ United Airlines pilot was forced into rehab for alcoholism. He actually had a concussion, lawsuit claims

Exclusive: Capt. Mike Tallon was sent for inpatient treatment, attended AA meetings, and blew into a breathalyzer twice daily, when he says he should have been treated for head trauma

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.

Oklo, NuScale, Hims Defy Trump Tariffs - And Power The Russell 2000 Toward New Highs

As tariff fears ripple across markets with President Donald Trump sending tariff letters to 12 countries, small-cap resilience is stealing the spotlight. The Russell 2000 index is soaring toward creating new all-time highs. The iShares Russell 2000 ETF (NYSE:IWM), which tracks the Russell 2000 index, is up over 25% from…

The Independent UK

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

1 2 3 4 5

People

198,323 stories

Gabriel OsorioMazilli

Jeffrey Neal Johnson

Jordan Chussler

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

the Federal Reserve

United Airlines

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

390,166 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play